Cheat sheet

Quick reference

Next up+10 XP
NurseSavvy Cheat SheetProcedure

Cancer Screening Guidelines

Cancer screening targets ASYMPTOMATIC, average-risk people to detect disease early. Start ages anchor the high-yield NCLEX facts: Pap at 21, mammogram at 40, colonoscopy at 45, low-dose CT for eligible smokers at 50. USPSTF and ACS guidance occasionally differ; the NCLEX usually tests USPSTF and may offer ACS as a valid alternative. Risk factors (BRCA mutation, first-degree relative, prior chest radiation) warrant earlier and more frequent screening.

The three most heavily tested screenings by start age, interval, and modality. Higher-risk clients start earlier and may need additional modalities (e.g., breast MRI).

Average-risk start age and interval

BreastCervicalColorectal
Start age402145
IntervalEvery 1-2 yearsPap q3yr; HPV q5yrColonoscopy q10yr; FIT annual
Primary testMammographyPap / HPVColonoscopy or FIT
Stop / upper age~74 (USPSTF)65 if prior normal75, then individualize

Breast

Start age
40
Interval
Every 1-2 years
Primary test
Mammography
Stop / upper age
~74 (USPSTF)

Cervical

Start age
21
Interval
Pap q3yr; HPV q5yr
Primary test
Pap / HPV
Stop / upper age
65 if prior normal

Colorectal

Start age
45
Interval
Colonoscopy q10yr; FIT annual
Primary test
Colonoscopy or FIT
Stop / upper age
75, then individualize
Low-dose CT
Lung: annual, ages 50-80, 20 pack-year history, currently smoke or quit within 15 years
Both age AND pack-year criteria required
Lung: neither alone qualifies
PSA shared decision-making
Prostate: men 55-69 discuss benefits vs harms; NOT universal screening
No PSA screening at age 70+
USPSTF recommends against routine PSA in men 70 and older
Chest X-ray not recommended
No mortality benefit for lung screening; only LDCT proven
Screening is for asymptomatic clients
Any symptom moves the workup from screening to diagnosis
Positive screen requires confirmation
High-sensitivity screens yield false positives; confirm with a specific diagnostic test
Lead-time bias
Earlier diagnosis lengthens apparent survival without delaying death
Overdiagnosis
Screening can detect indolent cancers that never cause harm
Mortality reduction confirms benefit
Population mortality, not survival rate or detection count, proves a program saves lives
Individualize by age and risk
BRCA, family history, or prior radiation start earlier
HPV vaccination does not replace screening
Vaccinated clients still need cervical screening
Address structural barriers
Cost, transportation, insurance, clinic hours; use mobile units and patient navigators
Culturally tailored outreach
Knowledge alone does not raise rates when structural inequities persist
Pair lung screening with cessation counseling
Every LDCT visit includes tobacco cessation support
When in doubt, discuss screening options
Shared decision-making is always a safe NCLEX answer
Report Nowescalate immediately
Abnormal Pap or positive HPV result
Refer for colposcopy/diagnostic workup
Positive FIT or FOBT
Requires diagnostic colonoscopy, not repeat screening
New breast lump
Symptomatic finding needs diagnostic imaging, not screening
Rectal bleeding
Symptom moves client to diagnostic evaluation
Suspicious low-dose CT nodule
Timely diagnostic follow-up and referral

Clinical Pearl

Screening is for the ASYMPTOMATIC: Pap at 21, mammogram at 40, colonoscopy at 45, lung CT for 20-pack-year smokers at 50 — but any symptom or positive result moves the client from screening to diagnosis.

NurseSavvy™·nursesavvy.com

Ready to practice this topic?

Get a personalized study plan built around this topic — free to try, no card needed.